Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Histotripsy versus Established Thermal Ablation Technologies: A Comparative Analysis of FDA MAUDE Adverse Event Reporting Patterns.

Created on 17 Nov 2026

Authors

Ashima Kundu, Alda Tam, Lili Zhao, Robert J Lewandowski, Andrew C Gordon

Published in

Radiology. Volume 321. Issue 2. Pages e261687.

Abstract

Background Histotripsy recently received U.S. Food and Drug Administration (FDA) clearance for liver tumors, but long-term safety data remain limited. Purpose To characterize histotripsy-related adverse events (AEs) reported to the Manufacturer and User Facility Device Experience (MAUDE) database during the early postmarket period and contextualize findings in comparison to microwave ablation (MWA) and radiofrequency ablation (RFA) during comparable observation windows. Materials and Methods A retrospective analysis of the FDA MAUDE database was conducted. AE reports were analyzed over comparable 24-month postmarket periods: July 2024 to July 2026 for histotripsy, January 2017 to January 2019 for MWA, and January 2016 to January 2018 for RFA. Reports were classified by severity (malfunction, serious injury, and death) and medical problem category. Firth-penalized reporting odds ratios (RORs), relative risks (RRs), and Bayesian modeling using Bass model-derived procedure volumes enabled exploratory denominator-adjusted comparisons. Results Of 570 AE reports initially identified, 506 met the inclusion criteria and were included in the final analysis (71 histotripsy [median patient age, 68 years; IQR, 56-76 years] and 435 MWA/RFA [median patient age, 58 years; IQR, 50-67 years]). Serious injury and death occurred in 86% (61 of 71) and 14% (10 of 71) of histotripsy reports versus 20% (89 of 435) and 2% (eight of 435) of MWA/RFA reports. Histotripsy had higher reported odds of serious injury (ROR, 14.24 [95% CI: 6.29, 35.56]; P < .001) and death (ROR, 4.35 [95% CI: 1.08, 24.35]; P = .04). In exploratory analyses using modeled procedure volumes, estimated RRs based on reported events were 6.11 (95% CI: 2.64, 14.11; P < .001) for serious injury and 10.94 (95% CI: 4.73, 25.33; P < .001) for death. Although sparse event counts produced imprecise estimates for some complication categories, histotripsy showed higher reporting odds of renal and urinary complications (P < .001), hemorrhage and vascular injury (P < .001), and gastrointestinal and/or abdominal complications (P < .001) in the full cohort. A sensitivity analysis excluding malfunction-only reports showed similar organ system reporting patterns. Conclusion Histotripsy demonstrated higher reported frequencies of serious AEs and death in early postmarket MAUDE surveillance compared with pooled MWA/RFA; however, differences in technology maturity and reporting era may have contributed to differential AE reporting, warranting prospective evaluation. © RSNA, 2026 Supplemental material is available for this article.

PMID:
43043182
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement